EFFECTS OF LEPTIN ON ESTABLISHED GLIOBLASTOMA CELL LINES by Cook, Nicholas J
Northern Michigan University
NMU Commons
All NMU Master's Theses Student Works
8-2014
EFFECTS OF LEPTIN ON ESTABLISHED
GLIOBLASTOMA CELL LINES
Nicholas J. Cook
Northern Michigan University, nichcook@nmu.edu
Follow this and additional works at: https://commons.nmu.edu/theses
Part of the Cancer Biology Commons
This Open Access is brought to you for free and open access by the Student Works at NMU Commons. It has been accepted for inclusion in All NMU
Master's Theses by an authorized administrator of NMU Commons. For more information, please contact kmcdonou@nmu.edu,bsarjean@nmu.edu.
Recommended Citation

























Northern Michigan University 
In partial fulfillment of the requirements 
For the degree of 
 
 
MASTER OF SCIENCE 
 
 










SIGNATURE APPROVAL FORM 
 
Title of Thesis: EFFECTS OF LEPTIN ON ESTABLISHED GLIOBLASTOMA CELL 
LINES 
 
This thesis by Nicholas J. Cook is recommended for approval by the student’s Thesis 
Committee and Department Head in the Department of Biology and by the Assistant 




Committee Chair: Robert Winn, Ph.D.                                                   Date 
 
____________________________________________________________ 
First Reader: Robert Belton, Ph.D.                                                         Date 
 
____________________________________________________________ 
Second Reader: Johnathan Lawrence, Ph.D.                                          Date 
 
____________________________________________________________ 




Department Head: John Rebers, Ph.D.                                                   Date 
 
____________________________________________________________ 
Dr. Brian D. Cherry                                                                                Date 









Nicholas J. Cook 
 
 Glioblastoma is one of the most difficult cancers to treat because it is aggressive 
and resistant to therapy. The discovery of new therapeutic targets is drastically needed as 
zero improved treatment options have been added to the standard of care over the past 15 
years. New and promising therapeutic targets are arising from psychosocial and 
environmental enrichment studies examining the role of stress in cancer progression. In 
animal models, eustress appears to slow tumor growth and recurrence resulting in 
increased overall survival and progression free survival while distress is associated with 
decreased overall survival. The cellular pathways activated by eustress were examined in 
glioblastoma cell lines; leading us to examine the use of β3 adrenergic stimulation to 
decrease leptin gene expression as a possible novel therapeutic. The role of leptin and β3 
adrenergic stimulation were examined using a cell viability assay to assess changes in 
proliferation and quantitative PCR to assess gene expression. With the use of a selective 
β3 agonist, leptin and leptin receptor mRNA was down regulated and resulted in 
decreased cell proliferation. Leptin’s observed role in glioblastoma cell proliferation and 
survival was supported by treatments with a leptin antagonist, resulting in decreased 
cellular proliferation. This evidence would suggest further examination of leptin as a 
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Many cancers have seen a vast improvement in progression-free survival or time 
without recurrence and prognosis in the last decade; the same is not true of glioblastoma 
multiforme (GBM). GBM is the most common and aggressive form of primary brain 
tumor. Each year 3.25 per 100,000 Americans will be diagnosed with GBM1 with a 
progression free survival of often less than one year and statistics from 1995-2009 
indicate a median one year prognosis of 35.7%2. The current standard of care for GBM is 
surgical resection and radiation followed by treatment with the chemotherapeutic agent 
temozolomide. The addition of temozolomide to the standard of care, nearly 15 years 
ago, increased the median survival from 12 months to 14.6 months3. Given the relatively 
poor prognosis, it is essential to investigate new forms of therapy.  
Using an animal model to examine the relationship of stress and cancer, it was 
demonstrated that an enriched environment decreased the satiety hormone, leptin and 
significantly slowed cancerous growth, by increasing apoptosis and decreasing 
proliferation4. While leptin has been shown to be oncomodulatory in a variety of cancer 
types, leptin’s role in glioblastoma is unknown5. However, leptin and leptin receptor are 
highly expressed in a majority of glioblastomas6. The objective of this work is to 
determine what effect leptin has on human glioblastoma cell lines and to examine the 






Chapter One: Literature review  
Cancer and Development 
 One of the earliest changes noted in neoplastic tissue is enhanced receptor 
tyrosine kinase activity. This may be due to an increase in the number of receptors or 
constitutive activation. These tyrosine kinases often play a role in development but are 
being co-opted by cancer cells to promote proliferation and survival7. Evidence would 
suggest that leptin is playing a similar role. Leptin has been shown to be important as a 
growth factor in intrauterine development8.  
Leptin was first implicated in increasing the aggressiveness of cancer 
(oncomodulation) by studies reporting the correlation between obesity and the occurrence 
or poorer prognosis with cancer. Studies showing that when chronic stress, like that seen 
with depression, was alleviated patients benefited both in time before recurrence and 
overall survival9 and some of this benefit may come from alteration in levels of leptin. 
Additionally, studies which implemented positive stress (eustress) as a treatment 
indicated a decrease in the rate of tumor growth by decreasing circulating leptin levels by 
increasing sympathetic nerve activation4.  
Stress and Cancer Progression 
It has been shown that a diagnosis of cancer can lead to depression and depending 
on the type of cancer the range of patients suffering from major depressive disorder 
(MDD) may range from 2% to 49%10. Most of those patients will not seek treatment, it 
has been reported that the number of cancer patients experiencing major depression who 
seek treatment is only 10%10. Evidence suggests that stress, such as that seen with 
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depression, plays a role in poor prognosis as one meta-analysis found mortality rates are 
39% higher in patients suffering from MDD11.  
While negative stress, such as that seen in depression may have negative effects 
on prognosis, positive stress or the alleviation of negative stress may result in better 
outcomes.   For example the placebo used in clinical trials should have no clinical 
benefit, but in many cases, the control group of patients will have a better prognosis than 
their nonclinical trial cohort12. Additionally, in a study of 227 breast cancer patients 
enrolled in a support program designed to educate, reduce stress/anxiety and to form 
support groups the patients in the study saw increased progression free survival (2.8 
years) compared to controls (2.2 years)13. Further, those whose cancer recurred lived 
longer with intervention (6.1 years) compared to control (4.8 years)13. By alleviating 
neurological depressive symptoms a significant clinical benefit was achieved, yet the 
exact physiological mechanism is unknown.   
Environmental Enrichment 
In animal models it has been shown that housing animals in enriched 
environments may decrease stress levels and provided significant clinical benefits14. 
Environmental enrichment has inhibited tumor formation in transgenic mice (APC +/-) 
which spontaneously develop colon cancer4. In addition Cao et al. found that 
environmental enrichment reduced the growth of orthotopically injected melanoma (B16 
cell line) when, compared to controls4. Tumor mass was reduced by 77% at 6 weeks post 
injection with several mice not developing an observable tumor until necropsy4. The 
physiological effect of environmental enrichment that slowed tumor growth was 
increased apoptosis, decreased cell proliferation along with an increase in natural killer 
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cell and cytotoxic T cell activity4. Further, an enriched environment increased 
progression-free survival, compared to non-enriched controls in lymphoma vaccinated 
mice15.  However, a recent study by Westwood attempting to replicate the impact of 
environmental enrichment on tumor growth found no statistical difference between 
standard housed mice and environmentally enriched mice but reported no molecular 
data16.  
Orthotopically injected mammary tumors in mice demonstrated that 
environmental enrichment increased apoptosis as measured by caspase 3 activity in 
environmental enriched mice versus control16. It was shown that when breast cancer cells 
(E0771) were treated with serum collected from an environmentally enriched mouse a 
20% decreased proliferation occurred compared to serum collected from standard 
enriched mice after 24 hours of treatment17.  
 By examining molecular changes it was determined that cancerous growth was 
inhibited by environmental enrichment through activation of the hypothalamic-
sympathoneural adipocyte axis (HSA) described by Cao4. HSA pathway is initiated by 
increased expression of the immediate early gene brain derived neurotropic factor 
(BDNF), that in turn activates the sympathetic innervation of adipocytes via the β-
adrenergic receptors leading to decreased leptin expression. Cao showed environmental 
enrichment on average decreased circulating leptin levels by 13% compared to control4. 







Adrenergic Signaling and Leptin in Adipose Tissue  
While the HSA axis innervates adipocytes, the sympathetic branch of the 
autonomic nervous system can also effect the release of the catecholamines, epinephrine 
and norepinephrine.  Epinephrine is released by the adrenal glands when stimulated 
during a stress response which is most commonly caused by an emotional response18 or 
exercise19. A multitude of adrenergic receptors (α and β) exists to which epinephrine can 
bind causing varied effects, either stimulatory or inhibitory. These receptors are 
widespread throughout the body with different tissue types being predisposed to 
expressing different types of adrenergic receptors. While β1 and β2 adrenergic receptors 
are wide spread throughout the body β3 adrenergic receptors are limited in their 
distribution to bladder, colon, and brown adipose tissue in humans20.  
When comparing obese animals to healthy weight animals, the β3 adrenergic 
receptor (β3AR), a thermogenic receptor in brown adipose tissue which helps maintain 
body temperature, was found to be down regulated in the obese animal in brown adipose 
tissue21. The infusion of epinephrine into human subjects has been shown to decrease 
circulating leptin levels22.  A study by Getty aimed at determining which β adrenergic 
receptor subtype (1-3) inhibited leptin release reported that β3 adrenergic receptor 
activation inhibited leptin secretion but found no inhibition with activating β1 and β2 
adrenergic receptors 
23. Comparing rodent studies to humans, rodents express high 
amounts β3AR on white adipose tissue while humans primarily have β3 adrenergic 





Leptin acts to signal satiety as it acts as an indicator of fat stores in the central 
nervous system and modulates energy balance and feeding behavior through acting on the 
hypothalamus25. Leptin was discovered by Zhang who mapped out the mutation 
responsible for creating phenotypically obese mice (ob/ob mice) which lacked leptin26. 
When supplemented with exogenous leptin these ob/ob mice returned to a normal 
weight26. Another type of obese mouse named db/db lack a functional leptin receptor 
resulting in increased leptin levels27. Yet, the majority of obesity in humans does not 
appear to be caused by a lack of leptin or dysfunctional leptin receptors. Instead, obese 
individuals have high levels of adipose tissue; the main source of leptin, which results in 
elevated serum levels of leptin and decreased sensitivity28. A link to leptin and cancer 
was postulated when obesity was found to be strongly associated with a greater risk of 
developing cancer29,30.  
Leptin’s Oncomodulatory Role  
While systemic leptin can act on cancerous growth, leptin also acts locally as a 
paracrine factor secreted by several tumor types and binds to leptin receptors on adjacent 
cancerous cells being independent of systemic leptin. The overexpression of leptin (or its 
receptor) occurs in many cancers including ovarian31, colorectal32 and breast cancer33 but 
leptin is not found in surrounding tissue. 
 Leptin has been shown to be oncomodulatory or increase the invasive and 
aggressive abilities in colon cancer34, prostate cancer35, neuroblastoma36, and 
glioblastoma5. In brain tumors, leptin and leptin receptor are overexpressed but not 
expressed in normal brain tissue and in lower grade tumors6. In GBM and anaplastic 
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astrocytoma 80.5% of 87 samples from Riolfi’s study were positive for leptin and its 
receptor while lower grade brain tumors (gangliogliomas and grade 1 and 2 
astrocytomas) had lower levels of expression of leptin and its receptor6. This study 
reported a significant correlation between leptin and leptin receptor with the degree of 
brain tumor malignancy6.  
The molecular basis for leptin’s oncomodulatory effect is attributed to activation 
of proliferative and anti-apoptotic pathways. It was demonstrated that decreasing leptin 
expression by 50% using siRNA increased apoptosis of rat C6 GBM cells in vitro37. The 
MAPK and JAK/STAT pathway are known to be activated by leptin to mediate 
proliferation38,39 (Figure 1). Leptin activates the PI3K pathway to protect against 
apoptosis40. Little is known about leptin’s role in GBM in humans. While the direct 
actions of leptin in GBM is unclear, one of the downstream signaling pathways of the 
leptin receptor (STAT3) when inhibited by siRNA significantly decreased cell 
proliferation in human GBM cells41.   
 Leptin has also been shown to act as an independent angiogenic factor via the 
PI3K and MAPK pathways, as well as acting synergistically to increase the expression of 
vascular endothelium growth factor (VEGF)42. Activated VEGF receptor also acts 
through the same signaling pathways as leptin receptor activation (PI3K and MAPK) for 
its effect43. Both VEGF and leptin are upregulated during hypoxia which is of importance 
as the microenvironment of GBM can be extremely hypoxic with as little as 0.1% 
oxygen. Increased hypoxia was been associated with increased aggressiveness of the 
tumor44. Angiogenesis is mediated by increases in hypoxia inducible factors (HIF) 1 and 
2. Of these two subfamilies of HIF, HIF 2 increases during chronic hypoxia and HIF 1 
increases during acute hypoxia, it is HIF 1 that plays a larger role in angiogenesis. HIF 1 
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effects leptin and VEGF gene expression through a hypoxia response element (HRE) in 
leptin’s promoter region45. Hypoxia driven leptin expression has been described in 
colorectal cancer as well as in adipose tissue34.  
 
 
Figure 1: Cell signaling pathways co-opted by cancer through leptin receptor (ObR) 
activation5. Pathways include the Janus Kinase (JAK), Signal Transducer and Activator 
of Transcription 3 (STAT) and the Mitogen Activated Protein Kinase (MAPK) signaling 
cascade both of which lead to increased cell proliferation. The MAPK and 
Phosphoinositide 3-kinase (PI3K) signaling pathway both lead to increased invasiveness 
by enhancing migration and angiogenesis or vascularization of the tumor. Also the PI3K 
and JAK-STAT pathway provide apoptosis resistance. Inhibition of leptin includes Super 
human leptin antagonist which inhibits leptin from binding to its receptor and β3AR 
agonist which down regulated leptin and leptin receptor gene expression while hypoxia 
through HIF 1 increase leptin gene expression. 
 
 




Leptin appears to have a role in providing resistance to various cancer treatments 
coupled to its oncomodulatory role. Leptin has been found to inhibit the efficiency of the 
antiestrogen ICI 182,780 in breast cancer, possibly through the activation of the JAK-
STAT pathway46. These effects support clinical data that obesity (increased circulating 
leptin) increases the resistance to antiestrogen therapy46. Additionally, leptin has been 
shown to decrease the cytotoxicity of fluorouracil (5-FU) in colon cancer, although the 
specific mechanism is unknown, and may be due to the apoptotic resistance leptin 
provides47.   Bevacizumab is an anti-VEGF treatment used in colon cancer and it has 
been demonstrated that a greater proportion of visceral fat has been correlated with 
poorer prognosis48,49. In GBM, Bevacizumab provides a minimal change in progression 
free survival at 6 months from 32% to 42%50. As VEGF is inhibited from binding, leptin 
remains present. Heightened acute hypoxia may drive the expression of leptin which can 
then act independently as an angiogenic factor and the tumor will still become 
vascularized51. As leptin plays an oncomodulatory role in many cancer and is highly 
prevalent in GBM providing resistance to current therapies it is essential to investigate 
leptin’s role in GBM. 
Project Objectives 
 With mounting evidence that leptin increases GBM aggressiveness and provides 
resistance to treatment, coupled with evidence that GBM overexpresses leptin, it is 
essential to further examine leptin’s effects in GBM. The effect of β3AR activation on 
GBM cells will be examined in this paper. In adipose tissue, stimulating β3 adrenergic 
receptors results in decreased leptin secretion and it is known that, in some cancers, β3AR 
is unregulated, however the status of β3 adrenergic receptor is unknown in GBM. We 
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hypothesize that a β3AR agonist will decrease leptin gene expression and decrease 
glioblastoma cell proliferation. Additionally, we anticipate that use of a high affinity 
leptin receptor antagonist, to inhibit leptin from binding to leptin receptor, will also 
decrease GBM cell proliferation and provide additional evidence of leptin’s role in GBM.  
 
Chapter Two: Experimental Design  
Introduction 
While leptin has been found to be overexpressed in a high percentage of GBM 
patient samples it is unknown whether established GBM cell lines (T98, LN229) express 
leptin and leptin receptor. β3AR agonists are a potent inhibitor of leptin in adipocytes. 
While it is known that β3ARs are upregulated in colon cancer the expression status of 
β3AR and their role in leptin regulation of GBM cell lines is currently unknown. 
Amplification of mRNA for leptin and leptin receptor will be used to determine the 
presence of leptin in established GBM cells lines. The appearance of mRNA for β3 
adrenergic receptor will provide a possible treatment option to target leptin expression.  
GBM Cell Lines 
 
T98, LN229, and U87 GBM cell lines (American Tissue Culture Collection 
Manassas, VA) were cultured in standard conditions of 37°C and 5% CO2 in complete 
media, Eagle’s minimal essential medium (Lonza, Walkersville, MD) with 10% fetal 
bovine serum (FBS) (Atlanta Biological, Atlanta, GA) and 1% 
Penicillin/Streptomycin/Amphotericin B (Gibco, Carlsbad, CA)) until over 75% 




RNA Extraction   
 
 RNA was extracted using an RNAeasy kit (Qiagen, Germantown, MD) following 
the recommended protocol. Briefly, the supernatant was removed and the pelleted cells 
were suspended in 350 µl RLT buffer and vortexed. Cell lysate was then homogenized 
using centrifugation using the QIA Shredder spin column (Qiagen) following the 
manufacturer’s published protocol. RNA was then isolated from the cell lysate and stored 
at -20°C and converted to cDNA within 7 days.  
Reverse Transcriptase PCR  
RNA was converted to cDNA using the AMV reverse transcriptase kit (Promega, 
Madison, WI) following the manufacturer’s protocol. First 2 µl of RNA was added to a 
0.5 ml thin-walled PCR reaction tube along with 1 µl of random hexamer primers and 
heated to 70°C for five minutes then cooled on ice. Once cooled, the following 
components were added to the reaction: 5 µl of AMV Reverse Transcriptase 5X Reaction 
buffer, 2.5 µl of dNTP mix, 40 units of RNasin Ribonuclease Inhibitor, and 30 units of 
AMV reverse transcriptase (enzyme). The reaction was incubated at 37°C for 60 minutes, 
cDNA was stored at -20°C until further use. The cDNA was used for PCR amplification 
for the following genes: leptin ligand, leptin receptor, β3 adrenergic receptor and GAPDH 
(housekeeping gene). PCR reactions (25 µl) were set up according to manufacturer’s 
suggested protocol using 2x PCR Master Mix (Promega) (12.5 µl), forward and reverse 
primer set (1 µl each), cDNA template (5 µl), and nuclease free water (5.5 µl). PCR 
amplification was performed using an initial denaturation step at 95°C for 2 minutes, 
followed by 30 cycles: denaturation at 95°C for 30 seconds, annealing at 55°C for 30 
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seconds, and extension at 72°C for 30 seconds with a final extension at 72°C for 5 
minutes. PCR products were examined by running on a 1.2% agarose gel containing 0.5 
µg/ml ethidium bromide at 70 volts for 45 minutes in 1x (Tris-Borate EDTA, TBE, 
buffer). Products were visualized under ultraviolet light using a Molecular Imager Gel 
Doc (BioRAD, Hercules, CA). 
Designing PCR Primers  
Primer sets were designed for real time PCR using primer 3 on My Biology 
Workbench (http://workbench.sdsc.edu/). Then primer-BLAST was used to ensure 
specificity to target genes without the amplification of off-target mammalian homologues 
and IDT Oligo analyzer tools (http://www.idtdna.com) were used to ensure favorable 
annealing to target sequence rather than primer sets forming dimers.  
Primer Sets (Human) 
Table 1: IDT Primer sets used for amplification of human cDNA for reverse transcriptase 
PCR (RT PCR) and quantitative PCR (qPCR). DNA sequences shown in 5’ – 3’ 
orientation. 
Primer (Human) Sequence  5’ -  3’ 
Beta Actin Forward AAG GTG TGG TGC CAG ATT TTC 
Beta Actin Reverse TCG ACA ACG GCT CCG GCA T 
Beta-3 Adrenergic Receptor Forward TGA AAT CCA GTT GCC ATT GA 
Beta-3 Adrenergic Receptor Reverse ATT TGA CCA ACC CAA CA AT 
qPCR GAPDH Forward AGA GGG AGG GAT GAT GTT 
qPCR GAPDH Reverse TGC ACC ACC AAC TGC TTA 
RTPCR GAPDH Forward AAC TTT GGC ATT GTG AAG GGC TC 
RTPCR GAPDH Reverse TGG AAG AGT GGG AGT TGC TGT TGA 
Leptin Forward GAA GAC CAC ATC CAC ACA CG 
Leptin Reverse AGC TCA GCC AGA CCC ATC TA 
Leptin Receptor (V1-3) Forward TGG GTC TTC GTA TGA GGT TCA GGT 
Leptin Receptor (V1-3) Reverse GCT TTC CGC AAG TGA CTG GAT TGT 
 




  To determine the effects of leptin on GBM proliferation using the T98 and LN229 
cell lines, exogenous leptin was added to cell culture medium. To further investigate 
leptin’s role in proliferation of T98 and LN229 cells, anti-leptin therapies were used in 
vitro. These treatments included β3AR agonists (Sigma, St. Louis, MO) and Super 
Human Leptin Antagonist (Protein Laboratories Rehovot, Israel) to examine the effects 
of endogenous leptin. Endogenous leptin was expected to be depleted by down regulating 
the expression of leptin and leptin receptor via β3AR agonist stimulations. Blocking 
leptin from binding to its receptor with the Super Human Leptin Antagonist, the direct 
effects of endogenous leptin were further observed.  
Treatment of GBM Cell Lines  
T98 and LN229 cells were grown in standard conditions until 75% confluent at 
which time cells were removed by trypsin and pelleted at 300x g and were suspended in 
complete media. Cells were then counted using a hemocytometer and plated at 5,000 
cells in 100 µl per well in a 96 well plate (at least 6 wells for each treatment group) in 
complete media. Cells were allowed to adhere to the plate for 24 hours before media was 
removed and treatment added. Treatments consisted of Epinephrine (0.025 ng/ml-2.25 
ng/ml), β3 Adrenergic receptor agonist, BRL 37344, (400 ng/ml), recombinant leptin (200 
ng/ml), Super Human Leptin Antagonist, (200 ng/ml) and complete media as a control. 
Super human leptin required a vehicle control of 1% bovine serum albumin (BSA). 
Experiments were performed in triplicate or greater. Treatments were at physiologically 
relevant serum concentrations. Reported baseline serum levels of epinephrine is 0.05 
ng/ml, serum epinephrine levels have been reported to be 0.160 ng/ml for mild stressors 
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like mental arithmetic52 and 0.4 ng/ml in higher stress situations as measured during an 
oral presentation at a medical conference18.  
Quantifying Cell Proliferation 
To quantify the number of viable cells 100 µl of Cell Titer-Glo Luminescent Cell 
Viability Assay (Promega) was added to each well according to the manufacture’s 
protocol. After incubating at room temperature for 30 minutes luminescence was 
measured using a Modulus Microplate Reader (Promega). Cell Titer-Glo measures viable 
cells by quantifying the relative amount of ATP.  Experimental groups were reported as 
change of relative light units (∆RLU) from controls.  
Quantitative PCR  
RNA was obtained from 3 wells of a 96 well plate by removing the media and 
adding 112.5 µl of RLT buffer to each well. Cell lysate was homogenized as previously 
described and RNA extracted by RNeasy kit as previously described. RNA was 
converted to cDNA by AMV reverse transcriptase as previously described. Quantitative 
PCR was performed using Sybr Green Master Mix (Life Technologies, Carlsbad, CA) 
and following the manufacture’s protocol. Each reaction in a 48 well reaction plate (20 µl 
total) contained 2x Sybr Green Master Mix (10 µl), Forward and Reverse Primer (1 µl 
each of 10 nM primer), cDNA template (2 µl), and nuclease free water (6 µl in reactions 
with cDNA template and 8 µl in negative control wells). Reactions were performed in a 
StepOne Real-Time PCR System (Applied Biosystems, Carlsbad, CA) according to Sybr 
Green Master Mix cycling protocols; 10 minute incubation at 95°C for Taq polymerase 
activation, 15 second denaturation at 95°C , 60 second annealing step at 55°C, and 60 
second extension at 72°C for 40 cycles. Change in relative gene expression was 
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compared using the 2^-∆∆CT method as each PCR cycle difference should be a twoCT 
change in gene expression53.   
 
Statistical Analysis  
Data was analyzed using SPSS (Microsoft, Redmond, WA). Epinephrine and 
leptin data and leptin and β3AR agonist data were analyzed by one-way ANOVA. 
Tukey’s HSD was used as a post-hoc analysis to determine significant differences. A 
paired t-test was used to analyze qPCR data on the ∆CT between untreated and β3AR 
agonist for leptin ligand and leptin receptor in T98 and LN229 cell lines. Analysis of 
β3AR agonist and SHLA in LN229 cell line was conducted using a one sample t-test 
compared to untreated control. Interassay variability was assessed dividing the standard 
deviation of the treatment averages by the overall average, with an acceptable range of 
less than 20% variability between similar treatments. Intraassay variability was assessed 
by dividing the standard deviation of the sample by the average, with an acceptable range 
of less than 10% variability.   
CHAPTER THREE: RESULTS 
 
Identification of Leptin, Leptin Receptor and β3AR in GBM Cell Lines 
 
In T98, LN229, and U87 GBM cell lines, mRNA for leptin receptor, leptin ligand, 
β3AR, and GAPDH was amplified by rt-PCR (Figure 2). Amplification bands are easily 
observable for β3AR in T98, LN229, and U87 GBM cell lines. A faint band is present for 
leptin receptor in T98 and LN229 cell lines. A band for leptin was easily observable in 
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both T98 and LN229. Quantitative PCR amplified leptin and leptin receptor for 
comparison (Figure 6).  
 
Treatment with Epinephrine and Leptin is Not Additive  
 
Examining the role of stress in GBM with the use of epinephrine provided 
unexpected results. We asked the initial question of what effects sympathetic activation 
of adrenergic receptors would have on GBM cells in culture. Epinephrine has been shown 
to possess a broad range of effects acting upon multiple adrenergic receptors. 
Physiologically relevant levels of epinephrine (0.3 ng/ml to 0.5 ng/ml) observed in serum 
during a stress response as reported in the literature18,52 resulted in increased 
proliferation.  Cells treated with epinephrine proliferated with both basal (0.025 ng/ml to 
0.075 ng/ml) and high stress levels (0.3 ng/ml to 0.5 ng/ml) of epinephrine increased 
RLU approximately 10% from untreated cells (Figure 3). T98 cells treated with leptin 
showed a slight overall increase in growth at low levels (200ng/ml) compared to a 
negative change from control at higher concentrations (400 ng/ml) both of which were 
not significantly different from control.  However epinephrine at basal and stress levels in 
addition to leptin significantly decreased proliferation as measured by a 6-7% negative 
change in RLU from control.  
A one-way ANOVA was computed using SPSS to compare changes in relative 
light units from a cell viability assay. Six different treatment groups were compared: 
leptin treatment at 200 ng/ml (treatment 1), leptin treatment at 400 ng/ml (treatment 2), 
epinephrine at basal levels, 0.025 – 0.075 ng/ml, (treatment 3), epinephrine at high stress 
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levels, 0.3 -0.5 ng/ml, (treatment 4),  leptin 200 ng/ml in conjunction with basal levels of 
epinephrine (treatment 5), and leptin 200 ng/ml in conjunction with high stress levels of 
epinephrine (treatment 6). A significant difference was found among treatments (F(5,245) 
= 13.959, p<0.000). Tukey’s HSD was used to determine the nature of the differences 
between treatments. This analysis revealed that change from the control was highest in 
high stress epinephrine treatment (m = 10.23%, sd = 9.542%) and was significantly 
different from that of leptin 200 ng/ml (treatment 1: m = 1.81%, sd = 12.332%) and leptin 
400 ng/ml (treatment 2: m = -2.92%, sd = 18.485%). High stress epinephrine treatment 
was also significantly different from leptin and basal levels of epinephrine (treatment 5: 
m = -6.89%, sd = 16.162%) and significantly different from high stress epinephrine and 
leptin treatment (treatment 6: m = -7.34%, sd = 12.647). However, high stress 
epinephrine was not significantly different from basal levels of epinephrine treatment 
(treatment 3: m = 9.66%, sd = 8.22%). Basal epinephrine treatment was significantly 
different from both leptin treatments and leptin in combination of high and basal levels of 
epinephrine. Leptin treatment at 200 ng/ml was significantly different from treatment 
with leptin in combination with high and basal levels of epinephrine.   
Upon identifying leptin, leptin receptor, and β3AR mRNA in GBM cell lines and 
moderate response to epinephrine T98 and LN229 cell lines were treated with BRL37344 
a selective β3AR agonist to see what effects activating only the β3AR would have on cell 
growth.  
β3AR Agonist Effects Cell Proliferation 
Treating the GBM cell line T98 with BRL37344 decreased cell proliferation 
approximately 10% (Figure 4). When treated with 200 ng/ml of leptin GBM cells 
18 
 
proliferated at a rate similar to untreated cells. However, when cells were treated with 
leptin combined with a BRL37344 cell viability decreased by 9.5% on average (0% - 
9%). Intraassay variability was low in each plate (3.6% - 7.4%); however interassay 
variability was high 26% - 30%. A one-way ANOVA was computed using SPSS 
comparing change in relative light units in three different treatment groups; leptin 
treatment, leptin in conjunction with BRL37344, and BRL37344 alone. A significant 
difference was found among treatments (F(2,249) = 8.643, p<0.000). Tukey’s HSD was 
used to determine the nature of the differences between treatments. This analysis revealed 
that change from control was the least in leptin treatment (m = -4%, sd = 12.055%) and 
was significantly different from leptin/ BRL37344 agonist (treatment 2: m = -9.53, sd = 
10.39%) and BRL37344 agonist alone (treatment 3: m = -9.55, sd = 8.316%). However, 
the combination of leptin and BRL37344 agonist was not significantly different from the 
BRL37344 agonist treatment alone.  
  BRL37344 treatment alone deceased RLU by 10% in T98 and 15% in LN229 cell 
lines compared to control (Figure 9). A one sample t-test comparing the mean change in 
RLU of the BRL37344 treated groups to control found a significant difference between 
the means of each group and control. LN229 treated with β3AR agonist (t(23) = -6.374, p 
< 0.001) with a sample mean of -15.44% (sd = .11866) was significantly less than the 
control. T98 treated with BRL37344  (t(83) = -10.979, p < 0.001) with a sample mean of 
-9.96% (sd = 0.08316).   
β3AR Treatment and Leptin Expression  
Using qPCR on a subset of cells treated with a BRL37344 in T98 and LN229 cell 
lines expression of leptin and leptin receptor decreased (Figure 6). Gene expression levels 
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of untreated cells were compared with those of cells treated with 400 ng/ml of BRL 
37344. The collated data from six qPCR runs were as follows; the relative expression of 
leptin was reduced by 3%-34% when compared to controls, T98 leptin expression 
decreased to 97% of control, (range: 0.84 -1.12) p= 0.278 with overlap between standard 
error for treated and untreated and LN229 leptin expression decreased to 66% of control 
(range: 0.64- 0.68) p< 0.01. The relative expression of leptin receptor was reduced by 
36%-52% when compared to controls with T98 leptin receptor expression reduced to 
48% of control (range: 0.36 -0.63) p=0.05 and LN229 leptin receptor expression reduced 
to 64% (range: 0.58- 0.72) p= 0.0594. Significance determined using a paired (one tailed) 
t=test between BRL37344 treated and control ∆CT. 
Quantitative PCR on GBM cell lines T98, U87, and LN229 was used to compare 
the relative expression of leptin using beta actin as a house keeping gene (Figure 7). 
LN229 had the highest proportion of leptin arbitrarily set at 100% (range: 0.7 – 1.42) and 
U87 leptin levels at 85% (range: 0.61 – 1.2) and T98 leptin levels being the lowest 
relative amount 57% (range: 0.47 – 0.65).   
Super Human Leptin Antagonist 
Treating LN229 cell line with SHLA and BRL37344 as a negative control yielded 
decreased proliferation as measured by ∆RLU. SHLA decreased ∆RLU by 15.58% (p < 
0.001) on average while β3AR agonist decreased ∆RLU by 15.44% (p < 0.001) on 
average (Figure 8). Again intraassay variability was low ranging from 2.9% - 11.6%; 
however interassay variability was high 21.5% - 32.8%. A one sample t test comparing 
the mean change in RLU of the experimental to control groups found a significant 
difference between the means of both SHLA and BRL37344 and control. BRL37344 
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(t(23) = -6.374, p < 0.001) with a sample mean of -15.44% (sd = .11866) was 
significantly less than the control, super human leptin antagonist (t(29) = -13.562, p < 


















Figure 2: Identification of Leptin, Leptin Receptor and β3AR mRNA in GBM cell lines 
LN229, T98, and U87. Lane 1: 100 bp ladder, Lane 2: GAPDH-LN229, Lane 3: Leptin-
LN229, Lane 4: Leptin Receptor-LN229, Lane 5: β3AR-LN229, Lane 6: GAPDH-T98, 
Lane 7: Leptin-T98, Lane 8: Leptin Receptor-T98, Lane 9: β3AR-T98, Lane 10: 










Figure 3: Effect of leptin and epinephrine on proliferation of T98 GBM cell line. Cells 
were plated at a density of 5,000 cells per well and allowed to adhere over 24 hours. 
Media was removed and cells were treated with 200 ng/ml and 400 ng/ml of leptin, 0.025 
ng/ml -0.075 ng/ml of epinephrine (basal serum levels), 0.3 – 0.5 ng/ml of epinephrine 
(high stress serum levels), leptin in combination with basal levels of epinephrine and 
leptin in combination with high stress levels of epinephrine. After 48 hours of treatment 
relative cell change was determined using Cell Titer-Glo using change in relative light 
units (∆ RLU) from control as determined by a Modulus Microplate Reader. Significance 








































Figure 4: Effect of β3AR agonist on proliferation of T98 GBM cell line. Cells were plated 
at a density of 5,000 cells per well and allowed to adhere over 24 hours. Media was 
removed and cells were treated with 200 ng/ml of leptin, 200 ng/ml of leptin and 400 
ng/ml of BRL37344 and 400 ng/ml of BRL 37344 alone. After 48 hours of treatment 
relative cell change was determined using Cell Titer-Glo using change in relative light 
units (∆ RLU) from control as determined by a Modulus Microplate Reader. Significance 



























Figure 5: Effect of β3AR agonist on proliferation of T98 and LN229 GBM cell lines. T98 
and LN 229 GBM cell lines plated at a density of 5,000 cells per well in 12 wells and 
allowed to adhere over 24 hours. Media was removed and cells were treated with 400 
ng/ml of BRL37344 (β-3 adrenergic agonist). After 48 hours of treatment relative cell 
number was determined using Cell Titer-Glo using relative light units as determined by a 
Modulus Microplate Reader. ∆ RLU (the change in relative light units) was measured as 
compared to control. Analysis includes 4 separate 96 well plates. Three wells from each 
treatment groups were used to obtain mRNA to quantify relative expression levels of 
leptin and leptin receptor. Significance shown by single asterisk (*) represents p < 0.05 

























Figure 6: Relative gene expression of leptin receptor and leptin ligand in LN229 and T98 
GBM cell lines treated with BRL37344. Relative gene expression normalized using 
GAPDH using the 2-∆∆CT method. Change in gene expression from untreated cells (blue) 
of leptin ligand and leptin receptor with treatment of BRL37344 (β3AR agonist) (red) in 
LN229 and T98 GBM cell lines. Significance from control shown by single asterisk (*) 















































Figure 7: Comparison of leptin mRNA levels in LN229, U87 and T98 GBM cell lines. Leptin 
normalized relative to beta actin using the 2-∆∆CT method with cell lines leptin levels compared to 





















Figure 8: Effects of β3AR agonist and super human leptin antagonist on proliferation of 
LN229 cell line. LN229 GBM cell line plated at a density of 5,000 cells per well and 
allowed to adhere over 24 hours. Media was removed and cells were treated with 400 
ng/ml of BRL37344 (β-3 adrenergic receptor agonist) and 200 ng/ml super human leptin 
antagonist. After 48 hours of treatment relative cell number was determined using Cell 
Titer-Glo by using relative light units using a Modulus Microplate Reader. ∆ RLU (the 
change in relative light units) was measured as compared to control. Analysis includes 4 
plates.  Significance from control shown by double asterisk (**) represents p < 0.01. 
 




























CHAPTER FOUR: DISCUSSION 
Novel Findings 
 This investigation started with examining if leptin, leptin receptor and β3AR were 
expressed by GBM cell lines. This is the first reported finding of β3AR mRNA being 
present in GBM cell lines. While leptin and leptin receptor have previously been reported 
in rat C6 GBM cells and human GBMs, it is reconfirmed here. Following the finding of 
β3AR mRNA expression in GBM cell lines, activation of the β3AR down regulated leptin 
expression. This study demonstrated that β3AR was both functional and that activation of 
the receptor with a specific β3AR agonist resulted in decreased leptin and leptin receptor 
in LN229 glioma cells. Β3AR agonist treatment decreased cell proliferation as did the 
SHLA. These results indicated that targeting leptin signaling directly or indirectly may be 
beneficial in GBM. 
Exogenous Leptin  
 Addition of leptin to GBM cell lines had no overall effect. The lack of effect 
could be caused by saturation of the leptin receptor by endogenous leptin. It is also 
possible that the FBS used in culture of the cells may provide an additional source of 
leptin. It is well established that FBS contains a number of growth factors and other 
proteins, with its established role during development it would not be surprising if leptin 
is present in FBS. To observe the effects of exogenous leptin it may be necessary to 
deplete endogenous leptin (one possible method would be to use a short hairpin RNA for 
leptin) and assure that unwanted sources of exogenous leptin were eliminated. While 
exogenous leptin did not promote proliferation endogenous leptin is required for cell 
survival and continued cell growth.  
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Adrenergic Stimulation  
Nonspecific adrenergic receptor activation in GBM cell lines using epinephrine 
increased proliferation by 10% at levels consistent with basal (0.025 ng/ml -0.075 ng/ml) 
and serum stress levels (0.3 ng/ml - 0.5 ng/ml) of epinephrine. While leptin treatment 
alone produced little to no change in growth, combined treatment of leptin and 
epinephrine resulted in a significant decrease in proliferation of 6% -7%. If the decrease 
in proliferation seen with the combined treatment was due to activation of the β3AR a 
similar response would be expected with epinephrine alone. To observe the effects of 
β3AR in GBM cells a selective agonist, BRL37344, was used to treat the GBM cell lines. 
 When β3AR was activated by BRL37344 proliferation decreased between 10% 
(T98) and 15% (LN229) in following 48 hours of treatment. Treatment with BRL37344 
also decreased leptin mRNA by 3%-34% and leptin receptor mRNA by 36%- 52%. The 
largest decrease in proliferation (15%) occurred in LN229 GBM cells which 
proportionally have the highest expression of leptin as observed by quantitative PCR. 
Proliferation of T98 GBM cell line decreased by 10% following treatment with 
BRL37344 and experienced a 3% change in leptin mRNA and decreased leptin receptor 
by 52% on average. LN229 GBM cell line decreased proliferation by 15% following 
treatment with BRL37344 and leptin mRNA levels decreased 34% and leptin receptor 
mRNA levels decreased 36%.  
Examination of relative cell numbers using ATP as an indicator of live cells does 
not provide insight into the underlying cause of change in cell growth. It is not clear if the 
changes seen were due to decreased proliferation or to increased apoptosis. Both 
proliferation and apoptosis have been implicated as an oncomodulatory role of leptin in 
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other cancer types37-40. This study demonstrates that the GBM cell lines examined 
express leptin and leptin receptor, however the levels of leptin and leptin receptor has 
been shown to be variable and we suspect that inhibiting cell lines with greater 
expression of leptin would be the most susceptible to anti-leptin therapy.   
Leptin Antagonist 
Blocking the leptin receptor using SHLA decreased LN229 cell proliferation by 
15% similar to BRL37344. This decrease in proliferation following SHLA treatment 
provides further evidence of the role of endogenous leptin in GBM cell survival and 
proliferation. To fully appreciate the effectiveness of SHLA it will be necessary to 
examine changes in the leptin induced activation of the JAK-STAT pathway. The 
activation status of the pathway could be examined by monitoring the phosphorylation 
status of STAT3. 
Summary 
 While exogenous leptin did not increase cell number or proliferation, endogenous 
leptin appears to be important for continued cell growth. Leptin’s oncomodulatory role in 
GBM cell lines was demonstrated following the administration of BRL37344 or by 
blocking leptin from binding to leptin receptor. We report that blocking leptin receptor 
activation and decreasing leptin and leptin receptor levels significantly decreases GBM 
cell viability. The effectiveness of an anti-leptin therapy appears to be dependent on 
leptin expression levels. While the proportion of GBM tumors that express leptin and 
leptin receptor are relatively high (80%) some tumors may not be responsive to an anti-
leptin therapy6. However, with the evidence provided in this study that leptin plays an 
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oncomodulatory role in GBM it seems prudent to continue to investigate anti-leptin 
treatment strategies.  
FUTURE DIRECTIONS 
β3AR Agonist 
While leptin and leptin receptor mRNA levels decreased with BRL37344 
treatment, this may not be a suitable option for GBM patients. One of the many problems 
in treating GBM is getting drugs to pass through the blood brain barrier and to have high 
enough concentrations in the region of the tumor yet not be cytotoxic to the rest of the 
body. While the β3AR agonist BRL 37344 ability to cross the blood brain barrier is 
unknown, another selective β3AR agonist (Amibegron, SR-58611A) is known to readily 
cross the blood brain barrier and has gone through phase III clinical trials as a treatment 
for depression54. Studies determining the efficacy of Amibegron on tumor cells and 
alterations in leptin and leptin receptor expression are warranted.    
Metformin 
A new therapy in GBM is the diabetic drug metformin. In clinical trials 
metformin has given moderate increases in overall survival 14.6 months vs. 12.1 months 
and increased 2 year survival by 16% in GBM patients55. Metformin decreases serum 
leptin levels in humans56 and can reduce leptin levels below resistance in high fat diet 
(obese) rodents57. Also metformin has been shown to decrease growth and migration 
related to leptin stimulation in GBM cell lines58. One final finding of the effects of 
metformin on GBM is the inhibition of tumor initiating cells or cancer stem cells 
(CSC)59. When treated with metformin CSC showed decreased proliferation and sphere 
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formation was inhibited59. These observed effects may also be due to metformin’s effects 
on leptin. Not only are the effects of down regulating or inhibiting leptin signaling in 
established GBM cell lines which gives reason to investigate anti-leptin therapy further 
but emerging data in CSC would point at leptin as an important target in stopping 
recurrence. 
Cancer Stem Cells and Leptin 
CSC are a small population of cells that are resistant to current therapies that are 
the cause of recurrence in GBM. CSCs are able to recapitulate the tumor when a small 
number of cells (< 100) were injected into mice, while differentiated tumor cells are 
unable to form a tumor60. A recent study has shown CSC overexpress leptin receptor to a 
greater degree in GBM compared to differentiated tumor cells61. Breast CSC also have 
higher levels of leptin receptor compared to the differentiated tumor cells62. In mammary 
tumors, leptin is needed for stem cell proliferation and renewal62. Breast cancer cells 
derived from transgenic mice and then injected orthotopically into leptin deficient mice 
(ob/ob mice) did not form tumors as effectively as wild type mice63. Also db/db mice 
(obese mice with high leptin but nonfunctional leptin receptors) showed increased 
tumorigenesis when given orthotopical injections of cancer stem cells compared to wild 
type obese mice. A related finding has been observed in GBM CSC with inhibition of 
Stat3 inhibiting proliferation and CSC could not recover the ability to self-renew after 
Stat3 inhibition64. Due to these findings leptin will continue to be an important area of 






 In conclusion we have demonstrated that inhibiting leptin has anti-proliferative 
effects, which in itself may be a reason to further investigate leptin as an adjuvant therapy 
for GBM. While current experimental drugs for GBM, like metformin, may actually be 
targeting leptin further work investigating metformin’s effects on leptin in GBM are 
warranted. This study also demonstrates that treating GBM with a β3AR agonist may be 
equally valid based upon the number of GBMs expressing β3AR. New findings of 
leptin’s role in CSC proliferation and self-renewal makes leptin and even more promising 
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RLU change from untreated  














1.00 84 -.0400 .12055 .01315 -.0662 -.0138 -.39 .30 
2.00 84 -.0953 .10390 .01134 -.1179 -.0728 -.40 .10 
3.00 84 -.0996 .08316 .00907 -.1177 -.0816 -.39 .11 
Tota
l 
252 -.0783 .10678 .00673 -.0916 -.0651 -.40 .30 
Table 2: Statistical descriptive of T98 GBM cell line treated with 1. leptin (200 ng/ml), 2. 






   







.186 2 .093 8.643 .000 
Within Groups 2.676 249 .011   
Total 2.862 251    
Table 3: One way ANOVA comparing T98 GBM cell line change in RLU between 



























2.00 .05534* .01600 .002 .0176 .0931 
3.00 .05962
* .01600 .001 .0219 .0973 
2.00 
1.00 -.05534
* .01600 .002 -.0931 -.0176 
3.00 .00427 .01600 .961 -.0334 .0420 
3.00 
1.00 -.05962
* .01600 .001 -.0973 -.0219 
2.00 -.00427 .01600 .961 -.0420 .0334 
Table 4: Tukey HSD post hoc analysis of T98 GBM cell line treatment RLU change from 
untreated with the following treatments: treated with 1. leptin (200 ng/ml), 2. leptin (200 







RLU  change from untreated  
 N Mean Std. 
Deviation 
Std. Error 95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
1.00 60 .0181 .12332 .01592 -.0137 .0500 -.39 .21 
2.00 36 -.0292 .18485 .03081 -.0917 .0334 -.50 .48 
3.00 42 .0966 .08220 .01268 .0710 .1223 -.06 .26 
4.00 42 .1023 .09542 .01472 .0726 .1320 -.18 .30 
5.00 36 -.0689 .16162 .02694 -.1236 -.0142 -.43 .16 
6.00 35 -.0734 .12647 .02138 -.1168 -.0299 -.46 .11 
Total 251 .0133 .14695 .00928 -.0049 .0316 -.50 .48 
Table 5: Statistical descriptive of T98 treated with 1. leptin treatment (200 ng/ml), 2. 
leptin treatment (400 ng/ml), 3. epinephrine at basal levels, (0.025 ng/ml  – 0.075 ng/ml), 
4. epinephrine at high stress levels (0.3 ng/ml -0.5 ng/ml), 5. leptin (200 ng/ml) in 
41 
 
combination with basal levels of epinephrine, 6. leptin (200 ng/ml) in combination with 




deltaRLU   
 Sum of Squares df Mean Square F Sig. 
Between Groups 1.197 5 .239 13.959 .000 
Within Groups 4.201 245 .017   
Total 5.398 250    
Table 6: One way Anova of change in RLU in T98 GBM cell line between treatments 
leptin, epinephrine at basal levels, epinephrine at high stress levels, leptin and basal levels 
of epinephrine, leptin and high stress levels of epinephrine.   
 
Multiple Comparisons 
Dependent Variable:   deltaRLU   
Tukey HSD   
(I) treatment (J) treatment Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1.00 
2.00 .04730 .02761 .524 -.0320 .1266 
3.00 -.07850* .02635 .037 -.1542 -.0028 
4.00 -.08417* .02635 .020 -.1598 -.0085 
5.00 .08702* .02761 .022 .0077 .1663 
6.00 .09153* .02785 .015 .0115 .1715 
2.00 
1.00 -.04730 .02761 .524 -.1266 .0320 
3.00 -.12580* .02974 .000 -.2112 -.0404 
4.00 -.13146* .02974 .000 -.2169 -.0460 
5.00 .03972 .03087 .792 -.0489 .1284 
6.00 .04423 .03109 .713 -.0451 .1335 
3.00 
1.00 .07850* .02635 .037 .0028 .1542 
2.00 .12580* .02974 .000 .0404 .2112 
4.00 -.00567 .02858 1.000 -.0878 .0764 
5.00 .16552* .02974 .000 .0801 .2510 
6.00 .17002* .02997 .000 .0839 .2561 
4.00 
1.00 .08417* .02635 .020 .0085 .1598 
2.00 .13146* .02974 .000 .0460 .2169 
3.00 .00567 .02858 1.000 -.0764 .0878 
5.00 .17119* .02974 .000 .0858 .2566 
42 
 
6.00 .17569* .02997 .000 .0896 .2618 
5.00 
1.00 -.08702* .02761 .022 -.1663 -.0077 
2.00 -.03972 .03087 .792 -.1284 .0489 
3.00 -.16552* .02974 .000 -.2510 -.0801 
4.00 -.17119* .02974 .000 -.2566 -.0858 
6.00 .00451 .03109 1.000 -.0848 .0938 
6.00 
1.00 -.09153* .02785 .015 -.1715 -.0115 
2.00 -.04423 .03109 .713 -.1335 .0451 
3.00 -.17002* .02997 .000 -.2561 -.0839 
4.00 -.17569* .02997 .000 -.2618 -.0896 
5.00 -.00451 .03109 1.000 -.0938 .0848 
Table 7: Tukey HSD post hoc analysis of T98 GBM cell line treatment RLU change from 
untreated with the following treatments: 1. leptin treatment (200 ng/ml), 2. leptin treatment 
(400 ng/ml), 3. epinephrine at basal levels, (0.025 ng/ml  – 0.075 ng/ml), 4. epinephrine at 
high stress levels (0.3 ng/ml -0.5 ng/ml), 5. leptin (200 ng/ml) in combination with basal 








SHLA and b3 ln229 against control (0) 2 tailed  
 
One-Sample Statistics 
 N Mean Std. Deviation Std. Error 
Mean 
SHLA 30 -.1558 .06292 .01149 
β3AR 24 -.1544 .11866 .02422 
Table 8: Statistical description of SHLA and β3AR agonist treated LN229 against 









 Test Value = 0 








-13.562 29 .000 -.15580 -.1793 -.1323 
β3AR -6.374 23 .000 -.15438 -.2045 -.1043 
Table 9: One sample t-test comparing SHLA and β3AR agonist treated LN229 against 




 N Mean Std. Deviation Std. Error Mean 
LN229 β3AR 
24 -.1544 .11866 .02422 
T98 β3AR 84 -.0996 .08316 .00907 




 Test Value = 0 
t df Sig. (2-tailed) Mean 
Difference 




-6.374 23 .000 -.15438 -.2045 -.1043 
T98 β3AR -10.979 83 .000 -.09961 -.1177 -.0816 
Table 11: One sample t-test comparing β3AR agonist treated LN229 and T98 to control.  
 
 
 
 
 
